ERBB2 and gastric cancer: Currently, we are conducting a phase I clinical trial (ChiCTR2400089068) to explore the safety, tolerability, and preliminary efficacy of LDRT and SBRT in combination with CAPOX (capecitabine and oxaliplatin) and toripalimab as a first‐line treatment for HER2‐negative advanced GC/GEJC.